AT-rich interaction domain-containing protein 4B (ARID4B)

AT-rich interaction domain-containing protein 4B (ARID4B) is a chromatin-modifying protein that is part of the Sin3A histone deacetylase corepressor complex, involved in the regulation of gene expression, epigenetic modification, and chromatin remodeling[3][5]. It binds DNA via its Tudor domain and participates in the recruitment and assembly of corepressor and coactivator complexes at specific genomic loci. ARID4B modulates various cellular processes, including the regulation of cell proliferation, differentiation, apoptosis, and maintenance of the blood–testis barrier. It is implicated in cancer progression (especially as a potential oncogene or tumor suppressor depending on context), infertility, and hematologic disorders. The gene product has tissue-specific roles and is widely recognized as a biomarker and multifunctional regulator in both development and disease, but direct pharmacological targeting has not been reported[3][5].

Other names

AT-rich interaction domain 4BRBBP1L1RBP1L1SAP180Sin3-associated polypeptide p180BRCAA1breast cancer-associated antigen BRCAA1breast carcinoma-associated antigenretinoblastoma-binding protein 1-like 1histone deacetylase complex subunit SAP180180 kDa Sin3-associated polypeptide

Drugs targeting ARID4B would be expected to act through modulation of chromatin remodeling and epigenetic gene regulation, either by inhibiting or stabilizing its interaction with the Sin3A/HDAC corepressor complexes or affecting its ability to modulate gene expression[2][3][5]. Direct drug mechanisms are not established in current literature.